Physician profile
Alan D King
NPI 1649260704
$2,527.28
in general payments reported to CMS, 2019-2025
27 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $90.48 · 2022: $192 · 2023: $456 · 2024: $666 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $333.14 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $306.68 | 2019-2025 | |
| Novo Nordisk INC | $285.49 | 2022-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $179.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merit Medical Systems INC | $161.41 | 2024 | Endomaxx Stent and Delivery System |
| Merck Sharp & Dohme LLC | $136.10 | 2022-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Intuitive Surgical, INC. | $134.62 | 2025 | |
| Madrigal Pharmaceuticals | $127.12 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $126.23 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $115.22 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $97.76 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $71.77 | 2025 | |
| Lilly USA, LLC | $60.38 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $49.20 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $41.19 | 2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.79 | 2024 | Veozah |
| Itamar Medical INC | $37.37 | 2025 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $31.38 | 2019-2020 | |
| Genentech USA, INC. | $30.87 | 2019-2020 | |
| Boston Scientific Corporation | $29.64 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $28.98 | 2022 | |
| Corium, LLC | $24.56 | 2024 | Azstarys |
| Corcept Therapeutics | $20.33 | 2025 | Korlym |
| Amarin Pharma, INC. | $17.39 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.03 | 2023 | Qelbree |
| Phadia US INC. | $13.78 | 2019 | |
| Aytu Biopharma, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.